GLP-1 receptor agonists reduce major adverse cardiovascular events and slow chronic kidney disease progression in both diabetic and non-diabetic populations, with benefits that extend beyond their glucose-lowering and weight-loss effects. Large outcome trials demonstrate these cardiorenal protective effects occur independently of glycemic improvements alone. This comprehensive review positions GLP-1RAs as having evolved from simple diabetes medications into cornerstone cardiometabolic therapies with established multisystem benefits. The cardiovascular and kidney protection represents a significant paradigm shift in how we understand incretin-based therapies. These findings are particularly compelling because they suggest direct organ-protective mechanisms rather than secondary benefits from metabolic improvements. However, the review appropriately cautions against overstating benefits in areas like liver disease, sleep apnea, and neuroprotection, where evidence remains preliminary. The transition from diabetes-specific to broad cardiometabolic indication reflects one of the most successful therapeutic expansions in recent medicine. For adults concerned about cardiovascular aging and kidney health, this positions GLP-1RAs as potentially valuable beyond diabetes management, though cost and access remain practical barriers. The durability of these benefits and long-term safety profile will ultimately determine their role in preventive medicine.